Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07226999 · ClinicalTrials.gov registry record · Phase 2

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

A Phase 2 study of Small Cell Lung Cancer (SCLC), sponsored by Pfizer.

Recruiting
Registry status
Phase 2
Development phase
550
Enrollment target
6
Study locations

NCT07226999 is a Phase 2 study of Small Cell Lung Cancer (SCLC) that is actively recruiting participants, run by Pfizer. The registered enrollment target is 550 participants, above the 304-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (81% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07226999, a Phase 2 study of Small Cell Lung Cancer (SCLC), is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 2
Development phase
550 participants
Enrollment target
6
Study locations

Study Summary

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better. Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.

Conditions Studied

Small Cell Lung Cancer (SCLC)

Interventions

  • BIOLOGICAL Atezolizumab
  • DRUG Chemotherapy
  • DRUG PF-08634404

Study Locations (6)

Texas

  • Texas Oncology - San Antonio - San Antonio
  • Texas Oncology - Gulf Coast - Webster

Arkansas

  • Highlands Oncology Group - Springdale

Florida

  • Mid Florida Hematology and Oncology Center - Orange City

Osaka

  • Kansai Medical University Hospital - Hirakata

Other

  • Pan American Center for Oncology Trials, LLC - San Juan

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2025-12-09
Est. Completion 2034-03-11
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07226999

The ClinicalTrials.gov registry entry for NCT07226999 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 304-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (81% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT07226999 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Arkansas, Florida.

Frequently Asked Questions

What is clinical trial NCT07226999 about?

NCT07226999 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer". This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants m...

What is the current status of trial NCT07226999?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2025-12-09. Estimated completion is 2034-03-11.

What conditions does trial NCT07226999 study?

This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).

What interventions are being tested in trial NCT07226999?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), Chemotherapy (DRUG), PF-08634404 (DRUG).

Who is sponsoring clinical trial NCT07226999?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07226999 being conducted?

This trial has 6 study locations across Arkansas, Florida, Texas, Osaka, Other. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small Cell Lung Cancer (SCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small Cell Lung Cancer (SCLC)

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.